Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
13/10/2026 12:14
BRIEF-Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China Oct 13 (Reuters) - Wuhan Hiteck Biological Pharma Co Ltd 300683.SZ:
WUHAN HITECK BIOLOGICAL PHARMA CO - GRANTS VISARA EXCLUSIVE RIGHTS TO HT006.2.2 OUTSIDE GREATER CHINA
WUHAN HITECK BIOLOGICAL PHARMA CO - TO RECEIVE UPFRONT PAYMENT, MILESTONE PAYMENTS, AND TIERED ROYALTIES
WUHAN HITECK BIOLOGICAL PHARMA CO - PHASE 1B STUDY SHOWS 50% COMPLETE CORNEAL HEALING IN HIGHEST DOSE COHORT AFTER 8 WEEKS
WUHAN HITECK BIOLOGICAL PHARMA CO - TREATMENT-RELATED OCULAR ADVERSE EVENTS WERE MILD WITH NO STUDY WITHDRAWALS
Source text: ID:nPn8mF2bya
Further company coverage: 300683.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview